# CyPath Lung

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/cypath-lung-product
Canonical HTML page: https://gethealthbrief.com/entity/cypath-lung-product

## Recent coverage (2 stories)

### CyPath Lung Test Volume Up 216% as bioAffinity Adds Surveillance Use
2026-09-05 14:59:30 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

bioAffinity's CyPath Lung test volume grew 216% year over year, and the company is now expanding into post-treatment surveillance for lung-cancer patients. The move could widen the test's clinical role beyond initial diagnostic decisions.
Full story: https://gethealthbrief.com/story/cypath-lung-surveillance-volume-growth-health

### CyPath® Lung Sales Surge 200%: 3,000 Tests Mark Growing Acceptance
2026-07-08 00:57:29 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

bioAffinity Technologies reported a record Q2 for its CyPath® Lung noninvasive test, with sales more than doubling year-over-year and physician adoption accelerating. The test, designed to help evaluate indeterminate lung nodules, has now been used nearly 3,000 times across pulmonology and VA settings. The trend underscores the demand for noninvasive early cancer diagnostics in an expanding screening population.
Full story: https://gethealthbrief.com/story/cypath-lung-sales-200-percent-growth-q2-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.